Allergan (AGN) Balance Sheet

Click line-items for a historical chart and %

Current assets:
Cash and equivalents	4.91B
Short-term investments	55M
Trade receivables, net	914.5M
Inventories	296M
Other current assets	694.3M
Total current assets	6.87B
Investments and other assets	271.9M
Deferred tax assets	86.9M
Property, plant and equipment, net	1.01B
Goodwill	2.39B
Intangibles, net	1.79B
Total assets	12.42B
Current liabilities:
Notes payable	72.1M
Convertible notes
Accounts payable	287.4M
Accrued compensation	292.8M
Other accrued expenses	905M
Income taxes	0
Total current liabilities	1.56B
Long-term debt	2.09B
Other liabilities	1.01B
Commitments and contingencies
Allergan, Inc. stockholders' equity:
Preferred stock, $.01 par value; authorized 5,000,000 shares; none issued	0
Common stock, $.01 par value; authorized 500,000,000 shares; issued 307,512,000 shares as of June 30, 2011 and December 31, 2010	3.1M
Additional paid-in capital	3.35B
Accumulated other comprehensive loss	-408.6M
Retained earnings	5.89B
Stockholders' equity subtotal before treasury stock	8.84B
Less treasury stock, at cost (2,210,000 shares as of June 30, 2011 and 1,987,000 shares as of December 31, 2010)	-1.09B
Total stockholders' equity	7.75B
Noncontrolling interest	10M
Total equity	7.76B
Total liabilities and equity	12.42B

Entities mentioned with AGN